KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Other Non-Current Assets: 2017-2024

Historic Other Non-Current Assets for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to $4.2 million.

  • Aquestive Therapeutics' Other Non-Current Assets fell 24.37% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year decrease of 24.37%. This contributed to the annual value of $4.2 million for FY2024, which is 22.34% down from last year.
  • Latest data reveals that Aquestive Therapeutics reported Other Non-Current Assets of $4.2 million as of FY2024, which was down 22.34% from $5.4 million recorded in FY2023.
  • In the past 5 years, Aquestive Therapeutics' Other Non-Current Assets registered a high of $7.8 million during FY2020, and its lowest value of $4.2 million during FY2024.
  • Its 3-year average for Other Non-Current Assets is $5.4 million, with a median of $5.4 million in 2023.
  • In the last 5 years, Aquestive Therapeutics' Other Non-Current Assets spiked by 2,639.86% in 2020 and then decreased by 22.34% in 2024.
  • Yearly analysis of 5 years shows Aquestive Therapeutics' Other Non-Current Assets stood at $7.8 million in 2020, then fell by 11.91% to $6.9 million in 2021, then dropped by 6.55% to $6.5 million in 2022, then decreased by 15.70% to $5.4 million in 2023, then decreased by 22.34% to $4.2 million in 2024.